Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Long-Term Debt Repayments (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Long-Term Debt Repayments for 4 consecutive years, with $1.8 million as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Long-Term Debt Repayments changed N/A year-over-year to $1.8 million, compared with a TTM value of $5.7 million through Dec 2019, changed N/A, and an annual FY2019 reading of $5.5 million, changed N/A over the prior year.
  • Long-Term Debt Repayments was $1.8 million for Q4 2019 at Larimar Therapeutics, roughly flat from $1.8 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $1.8 million in Q4 2019 and bottomed at $697000.0 in Q4 2015.
  • Average Long-Term Debt Repayments over 4 years is $991090.9, with a median of $772000.0 recorded in 2017.
  • Peak annual rise in Long-Term Debt Repayments hit 67.99% in 2017, while the deepest fall reached 8.4% in 2017.
  • Year by year, Long-Term Debt Repayments stood at $697000.0 in 2015, then rose by 8.46% to $756000.0 in 2016, then soared by 67.99% to $1.3 million in 2017, then skyrocketed by 43.23% to $1.8 million in 2019.
  • Business Quant data shows Long-Term Debt Repayments for LRMR at $1.8 million in Q4 2019, $1.8 million in Q3 2019, and $1.3 million in Q4 2017.